Objectives: The aim is to evaluate venous stent patency, the development of post-thrombotic syndrome, recurrence, quality of life and the optimal post-procedural anticoagulation regimen in the treatment of iliofemoral deep venous thrombosis. Method and results: EMBASE and Medline databases were interrogated to identify studies in which acute deep venous thrombosis patients were stented. Twenty-seven studies and 542 patients were identified. Primary, assisted primary and secondary patency rates 12 months after stent placement ranged from 74 to 95, 90 to 95 and 84 to 100%, respectively. The observed post-thrombotic syndrome rate was 14.6%. The incidence of stent re-thrombosis was 8%. In 26% of studies, patients received additional antiplatelet therapy. Quality of life questionnaires employed in 11% of studies, demonstrating an improvement in the chronic venous insufficiency questionnaire (22.67 AE 3.01 versus 39.34 AE 6.66). Conclusion: Venous stenting appears to be an effective adjunct to early thrombus removal; however, further studies are needed to identify optimal anticoagulant regimen and effect on quality of life.
Background
Acute deep vein thrombosis (DVT) of the lower limbs occurs in about 1.0 person per 1000 population per year and is associated with substantial morbidity. 1 The majority of symptomatic iliofemoral venous obstructions are secondary to an episode of DVT. It may be limited to the iliofemoral segment or contiguous from the calf to iliac veins. 2 Although anticoagulation effectively prevents thrombus extension, pulmonary embolism, death and recurrence, many patients develop venous dysfunction resulting in post-thrombotic syndrome (PTS). 3 PTS probably evolves from venous obstruction, venous incompetence caused by destruction of the venous valves in response to the acute thrombotic occlusion, or both. 4 There has been a shift in the treatment focus for patients with iliofemoral DVT towards the use of early thrombus removal strategies such as endovenous thrombolysis (e.g. catheter-directed thrombolysis (CDT) and percutaneous mechanical thrombectomy (PMT)) and/or thrombectomy with or without venous stents to lower the incidence of PTS. 5 Patients with PTS have a significantly decreased quality of life (QOL) 6 and the condition can result in a substantial psychological and economic burden. 7 Acute venous stenting is predominantly used in patients with residual venous outflow obstruction of the iliac and common femoral veins after early thrombus removal with CDT or PMT. 8 The indication for stent placement after thrombolysis in patients with acute DVT is the presence of residual stenosis, ideally diagnosed by multiplanar venography and the use of intravascular ultrasound (IVUS) at the end of the procedure. When venous stenosis is treated by venoplasty alone, it has a high rate of recurrence or complete resistance to balloon dilation.
In patients receiving venous stents after a DVT, anticoagulation and possibly antiplatelet therapy may play an important role in preventing recurrent thrombosis and pulmonary embolism. So far, the choice of agent, dosing and duration of anticoagulant and possibly antiplatelet therapy is unclear for patients with venous stents. The conventional anticoagulants have been shown to reduce the risk of recurrent DVT dramatically. However, their role in preventing DVT in patients with venous stents remains unclear. Antiplatelet therapy has proven to be safe and efficacious in patients with arterial stents, but the effect in patients with venous stents, with or without prior DVT again remains uncertain.
Moreover, the most recent American College of Chest Physician guidelines (2016) fail to discuss the possibility of stenting after thrombolysis in patients presenting with DVT. 10 Likewise, the most recent guidelines, such as the National Institute for Health and Care Excellence 11 and the European Society of Cardiology, 12 do not discuss the role of venous stenting as part of the treatment option for patients after DVT. 13 The aim of this review is to collate evidence on the effect of venous stent placement on venous patency after acute iliofemoral DVT and the subsequent development of PTS, as well as trying to evaluate the impact of different antithrombotic agents on venous stent patency.
Methods

Study selection
Research question, inclusion and exclusion criteria of the studies were specified in advance. The population of this review consists of patients who underwent venous stenting after acute venous thrombosis (with symptoms less than 14 days), often in combination with balloon venoplasty preceded by CDT and/or PMT or surgical thrombectomy as well. Only studies where the use of post-interventional antithrombotic therapy was addressed were included. Any study design with more than five stented participants was included.
All studies which included patients who were stented for chronic obstruction or which did not report primary or secondary outcomes were excluded.
Interrogation of MEDLINE and EMBASE databases using the OVIDsp (Ovid Technologies, Inc.) platform from 1946 up to mid-March of 2016 was undertaken using certain MeSH headings (Appendix 1). No publication date restrictions were imposed; however, the search was restricted to articles in English and Arabic. Further selection was made on title and abstract screening. The final selection of articles was made by two researchers independently (MAHT and AB) after reviewing the full text as per the Preferred Reporting Standards for Systematic reviews and MetaAnalysis (PRISMA). 14 
Quality assessment
The quality of the included full-text studies was assessed by using the Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE Working Group) guidelines. Studies were screened by two authors (MAHT and AB) and any discrepancies were adjudicated by a third author (AHD). Data extraction was also performed by two authors independently (MAHT and AB) regarding the study outcomes.
Data analysis
Venous stent patency rates in all of the included studies were assessed together with thrombosis recurrence, post-thrombotic manifestations, anti-coagulation used and the duration of therapy. The results were tabulated using Microsoft Excel (Version 1702, Redmond, USA). Statistical meta-analysis was performed using SPSS 20.0 software (IBM, USA) and RevMan5.3.5.
Results
Inclusion and quality assessment
The initial search strategy resulted in a total of 760 studies and, after applying exclusion criteria and screening title, abstract and full text, as per PRISMA guidelines, 27 studies were included in the qualitative synthesis and three articles used for quantitative synthesis ( Figure 1 ). The studies consisted of three systematic reviews, 13, 15, 16 three randomised controlled trials (RCTs) [17] [18] [19] and 21 cohort studies (eight prospective, [20] [21] [22] [23] [24] [25] [26] [27] 12 retrospective studies [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] and one study including two patient series). 40 Five studies 23, 28, 32, 33, 37 were included in whom the whole population was stented. In 19 studies between 16 24 and 81.2% 19 of the population was stented. In all included studies, the patients underwent lysis, venoplasty, stenting, with or without surgical thrombectomy and were prescribed anticoagulation and/or antiplatelet agents. Duplex or conventional venography was used in 24 articles to assess the 12-month primary patency rates, assisted primary patency rates and secondary patency rates. Other reported outcomes were PTS, recurrent DVT, QOL assessment methods as well as the type and duration of antithrombotic regimen used during post-operative period. Assessment of PTS was performed using various methods, namely, the Villalta
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Phlebology 34 (2) scale, modified Villalta score and venous clinical severity score (VCSS). The overall range of follow-up periods was from three months 28 to eight years. 40 Two studies were limited to short follow-up periods of three and six months, respectively. 17, 28 All the included studies reported data on anticoagulant therapy or antiplatelet therapy. Recurrence of deep vein thrombosis was reported as early recurrence (within one day to one month after the procedure) in 13 studies [18] [19] [20] 23, 24, 26, 27, 31, 32, 34, 35, 37, 38 and as late (within 1-2 years) recurrence in 17 of included studies. 17, 18, [20] [21] [22] [23] [25] [26] [27] [28] [29] [30] 32, 35, 37, 40 The findings of the search are summarised in Table 1 .
Level of the evidence and grading
The quality of evidence to support the use of deep venous stenting as part of treatment of acute lower limb venous thromboembolism is currently weak. The interpretation of results of the GRADE assessment are displayed in Appendix 2a, b and c. 41 Using the GRADE approach for four of the five defined outcomes, the quality of evidence was rated as 'low' as it largely pooled from cohorts and case series, and for the QOL, it was rated as 'high' since it was obtained from the available RCTs (Table 2 ). 
Risk of bias
The included studies were assessed for several key biases by MAHT and AB: selection bias, performance bias, detection bias, attrition bias and selective reporting bias. Attrition bias was deemed a high risk if the follow-up rate was less than 80%, in the absence of systematic examination of those participants who were lost to follow-up. Bias was also evaluated at outcome level using the GRADE assessment of the evidence. The bias risk assessment of included studies was presented and summarised in Figure 2 .
Outcomes
Patency rates
Long and short-term stent patency rates were assessed in all studies. Primary, assisted primary patency and secondary patency rates 12 months after stent placement ranged from 74 to 95, 90 to 95 and 84 to 100%, 32 respectively. 33 High patency rates were reported in all patients in a number of studies. 17, 18, 24, 31, 40 The overall stent patency rate of included studies was 87.8% (475/542) with follow-up period of 12-19.7 months. The overall patency data are listed in Table 1 .
Recurrent DVT
Twenty-six studies provided data regarding DVT recurrence with follow-up duration ranging between three and 68 months. 40 The incidence of re-thrombosis in the whole study population for all included studies ranged from 2 30 to 25%. 25, 27 The overall re-thrombosis rate was 8% (60/542) with mean follow-up period of 19.7 months. As well, the incidence of ipsilateral rethrombosis in studies in which the whole population were stented or with known number of stented patients ranged from 3.7 17 to 50% as early recurrence 27 and 20% as late recurrence. 23 The DVT recurrence data are tabulated in Table 1 .
PTS
PTS was assessed in 26/27 studies. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [34] [35] [36] [37] [38] [39] [40] In most of these studies, the Villalta-Prandoni scale, modified Villalta scale, 42 the VCSS 43 and the change of C in CEAP 44 classification were used. These scoring systems have been validated in different settings [45] [46] [47] and subsequently endorsed by the International Society on Thrombosis and Hemostasis. In 18% of the studies (5/27), PTS was reported based on the whole patient cohort receiving venous stents 17, 23, 28, 32, 37 ; two studies were in the context of symptomatic iliac vein compression syndrome or MayThurner syndrome presenting with acute DVT. 23, 37 All PTS data are tabulated in Table 1 .
The use of post-interventional antithrombotic therapy and optimal duration
In all included studies, patients received anticoagulant therapy in the form of either vitamin K antagonists, direct oral anticoagulant (Factor X inhibitors) or low molecular weight heparin for at least three months, with or without addition of antiplatelet therapy. The antithrombotic regimen was decided on either placement of venous stents in three studies 17, 25, 34 or the presence of a hypercoagulable state in seven studies [20] [21] [22] [30] [31] [32] 35 or both in one study. 39 The criteria used were not mentioned in the remaining 15 studies. In addition, antiplatelet therapy was not used as a solo therapy after venous stenting in any of our included studies. In seven studies, patients received additional antiplatelet therapy after CDT and/or PMT and stent placement 17, 21, 31, 34, 35, 37, 39 (Table 3) . Dual antiplatelet therapy (Aspirin þ Clopidogrel) were used in two studies 17, 35 and it was unclear in another study. 39 
QOL assessment
QOL was assessed in only 11% of included studies (3/27) using disease-specific QOL according to the chronic venous insufficiency questionnaire (CIVIQ) which is a disease-specific instrument to measure the impact of chronic venous insufficiency on patients' lives. 48 Furthermore, QOL was assessed by telephone (subjective patient perception of improvement) or by using the Wong Baker chronic pain method in two other studies. Of the three studies assessed by CIVIQ, only one (3.7%) reported QOL assessment between stenting and nonstenting groups. However, the remaining two studies assessed the QOL between two different interventions (CDT and USAT; ultrasound-assisted CDT groups) or between percutaneous endovenous intervention (PEVI) and control groups in which 81.2 19 and 14.7% 17 of their population were stented, respectively. In a study done by Engelberger et al., 19 in which 39 of 48 patients (81.2%) were stented, disease-specific QOL according to CIVIQ was similar in both study groups (28 AE 11.6 in the USAT, (19/24) group versus 26.2 AE 7.5 in the CDT, (20/24) group (p ¼ 0.55)). On the other hand, it was assessed in another trial performed by Meng et al. 18 using CIVIQ, in which the CIVIQ score was significantly different between the stenting and non-stenting groups (22.67 AE 3.01 versus 39.34 AE 6.66, respectively) with P value < 0.001.
Discussion
After early thrombus removal for acute iliofemoral DVT, venous stenting is often performed in case of 
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Phlebology 34 (2) residual thrombi or obstructive lesions appearing to be resistant to venous angioplasty. 30 Overall, the evidence supporting the use of venous stents after a DVT in the iliofemoral area for improved short-and long-term patency appears reduced, in addition, with limited methodological quality. This review emphasises that additional stenting should have its proper indications, and unfortunately the available literature does not add a lot, to help the clinician in decision making, as indications/criteria for stent placement have rarely been validated so far. The lack of comparator studies is evident with only two studies 17, 25 : (one RCT) 17 comparing PEVI plus anticoagulation to anticoagulation alone. In these studies, the PEVI þ anticoagulation group performed significantly better than the anticoagulation alone group in terms of patency, 25 recurrent venous thromboembolism and development of PTS. 17 Our search noted an overall patency rate of 87.8% with a low incidence of thrombosis recurrence (8%) over follow-up period of 12-19.7 months but with low level of evidence. Although this overall patency rate appears to confirm the efficacy of the procedure, these figures are affected by both the heterogeneity between studies due to the different proportion of stented patients in these studies and the low level of evidence as most of studies were case series. In addition, the overall venous stent patency did not show any significant variability in the consistency and thoroughness of patient characteristics and outcomes reporting among studies. This review shows an improved patency rate when patients were stented.
Because of the fact that only three papers, not truly RCTs involving stenting and non-stenting groups, a meta-analysis can be hardly drawn. Only one RCT was really randomised patients between stent and no stent, the one by Meng et al., 18 as after receiving CDT, the major branch of the distal iliac vein was completely patent in 155 patients with lower extremity DVT, and 74 of these patients with iliac vein residual stenosis of >50% were randomly divided into a control group (n ¼ 29) and a test group (n ¼ 45). The two other RCTs randomised patients between two treatment procedures, but not between stent/no stent. 17, 19 In all included studies, self-expandable and/or balloon expandable stents were used to maintain the patency within the treated venous segments following deep venous thrombolysis. Large numbers of the earlier studies made use of arterial stents, modified for venous application, so there is a need for further research using venous-specific stents which are now more commonly used in Europe.
Post-thrombotic symptoms were less prominent in patients with venous stents than in those without stents, with an overall incidence of 14.6%, but again, with a low level of evidence. Although it is ideal to include studies with follow-up periods up to two years when included studies are being assessed for PTS rate as separate outcome, one study performed by Engelberger et al. 19 reported PTS rate with follow-up period of three months.
Interestingly, the ATTRACT trial, 49,51 multicentre randomised trial to evaluate CDT for the prevention of PTS in patients with proximal DVT, reported PTS incidence rate of 46% at two years which is much more consistent with our systematic review. This difference could be interpreted by the way that PTS had been investigated using only Villalta scale which has been sufficiently validated for this purpose. In a few cases, some patients were asymptomatic although their stents were occluded. 23 This might emphasise the controversy about the guidance of venous stenting placement.
The importance of ensuring a true improvement in a patient's QOL and not just venous severity scores has recently been demonstrated in the setting of endovenous intervention, although the follow-up period was short (three months). 19 In contrast, a study performed by Meng et al. showed that VCSS and CIVIQ score were both significantly different between the test and control groups. Furthermore, the improvement of symptoms was more significant in the test group compared with the control group, suggesting that stenting in the iliac vein following thrombolysis can improve clinical efficacy. This study showed, that although postoperative CIVIQ score was lower, QOL was improved in both groups, with significantly better scores with iliac vein stenting, possibly due to the improved patency of the blood vessels. 18 Therefore, the link between stent patency, post-thrombotic symptoms and QOL requires further evaluation. On the other hand, the recently published ATTRACT trial 49, 51 showed that there was no significant difference between the two treatment groups in the change of venous disease-specific QOL (P ¼ 0.08) or general QOL (P ¼ 0.37) from baseline to 24 months follow-up. In our opinion, this no QOL difference may be attributed to that only 82/297 patients (28%) had received stenting in the interventional group and this not the case when evaluating the change in QOL between stent and no stent groups. Thus, it can underestimate the effect of stenting following acute venous thrombolysis. From our point of view, there is now a growing body of evidence to support venous stenting in both the acute and chronic setting, and as more patients receive stents, the production of stenting registries will hopefully further contribute to the evidence. PTS manifestations following iliofemoral DVT are seen less frequently when CDT in combination with adjunct therapy than with systemic or regional lysis therapy 16 alone is used. There remains much debate as to whether the addition of antiplatelet agents and their duration results in any improvement in patency. However, there could be an additional effect of aspirin, in addition to warfarin treatment, for the reduction in the prevalence of PTS. 17 It is noticed that prominent figures play in favour for adding antiplatelets as cornerstone in the antithrombotic regimen after venous stenting and their significant impact on various outcomes (Table 3) . However, the level of evidence supporting the optimal type and duration of antithrombotic regimen post stent placement is still lacking and further work is needed.
Based on the evidence presented in this review, no firm conclusions regarding the association between the duration of antithrombotic therapy and the study outcomes can be drawn. Although the extended anticoagulation regimen is generally determined by the underlying thrombotic risk factors and not guided by presence of venous stent placement, the optimal duration of anticoagulation following venous stenting in the setting of early thrombus removal has not been adequately studied, and no evidence-based recommendations can be provided.
There are therefore several areas for future research. Before the practice is more widely rolled out though, more randomised studies should be performed comparing the practice against conservative measures particularly between stenting and non-stenting groups, with longer term follow-up and outcome measures to include validated chronic venous disorder measures and QOL scores. 50 In addition, there is pressing need to raise a call to study parameters and determine optimal patient selection criteria when deciding to stent after acute thrombolysis based on anatomic (venographic and IVUS) and hemodynamic (duplex and venographic) determinants.
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Phlebology 34 (2) Limitations Most studies still have limited information especially regarding the long-term data. PTS and QOL evaluation were assessed by three different methods, although these methods were all individually validated; they add heterogeneity and inconsistency to the results. In addition, CIVIQ is validated for venous insufficiency 48 and not only for post-thrombotic status. Furthermore, PTS has been reported at three months follow-up period in one study 19 although it is ideal to report PTS outcome at two years follow-up and this ultimately affects the level of evidence of PTS outcome. One of the limitations of this review is that post-procedural antithrombotic therapy is not assessed separately as a potential factor for short-and long-term failure or success of the stenting procedure. Another limitation of this review was the heterogeneity (based on the variations and narrative compatibility of all included studies) and the low level in the quality of most of included studies as only a portion of patients underwent stenting within these studies. Furthermore, the absence of data regarding hemodynamic values measured by IVUS or duplex and detailed stent procedure complications in all cited studies.
Conclusion
Venous stenting for acute DVT patients appears to be an effective strategy of treatment with better patency, lower re-thrombosis and post-thrombotic rates and improved QOL of patients as well. Although the evidence for the use of venous stents in the context of acute venous thromboembolism is still lacking, it appears promising and should therefore be considered as a treatment option, when indicated while the evidence base is improved. Several bodies are not recognising stenting as part of treatment while managing acute iliofemoral DVT patients as stenting is a new topic and researchers should highlight how big groups have not identified this treatment modality. The review describes the scarcity of robust studies on the acute venous stenting with long-term data and it alerts the physicians to enhance further studies to confirm or to disregard the recommendations given in the present paper.
What this paper adds
This review demonstrates that quality of evidence behind the use of deep venous stenting following thrombolysis for treatment of acute deep venous thrombotic events is weak. This review is intended to influence clinical practice and to alert physicians to enhance further studies to confirm or to disregard the recommendations given in the present paper.
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